Tifcemalimab | Interleukin Related interleukin-related.com

Product Name :
Tifcemalimab

Search keywords :
Tifcemalimab

drugId :
null

Target Vo:
B- and T-lymphocyte attenuator

Target Vo Short Name :
BTLA

Moa_Name:
Anti-BTLA

First Approval Country :

First Approval Date Filter:
null

Origin Company_Name :
Shanghai Junshi Biosciences Co Ltd

Active Company_Name :
Fudan University

Active Indication_Name:
Hodgkin Disease

In Active Indication_Name:

Termination Status :

China Termination Status :

Highest Status:
Phase 3 Clinical

China Highest Status:
Phase 3 Clinical

Antibodies are immunoglobulins secreted by effector lymphoid B cells into the bloodstream. Antibodies consist of two light peptide chains and two heavy peptide chains that are linked to each other by disulfide bonds to form a “Y” shaped structure. Both tips of the “Y” structure contain binding sites for a specific antigen. Antibodies are commonly used in medical research, pharmacological research, laboratory research, and health and epidemiological research. They play an important role in hot research areas such as targeted drug development, in vitro diagnostic assays, characterization of signaling pathways, detection of protein expression levels, and identification of candidate biomarkers.
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
TNF alpha Antibody
Bim Antibody
Histone H2A(acetyl K9) Antibody: Histone H2A(acetyl K9) Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 14 kDa, targeting to Histone H2A(acetyl K9). It can be used for WB,ICC/IF,IHC-P,ChIP,CUT&Tag-seq assays with tag free, in the background of Human, Mouse.

Author: Interleukin Related

Related Posts